Two 'Esbelta' products, one named seller, and five substances the labels did not name
The FDA notified consumers about Esbelta Intense Loss and Esbelta Chupapanza Flat Belly on 18 August. This is not substitution and it is not underdosing — it is undeclared pharmaceutical ingredients, which no amount of label arithmetic would have caught.
The last story of this kind here was substitution — capsules sold as one plant that held another. This is the neighbouring failure. Nothing was swapped in these products; something was added.
On 18 August the Food and Drug Administration advised consumers not to purchase or use Esbelta Intense Loss and Esbelta Chupapanza Flat Belly, both promoted and sold for weight loss on various websites and possibly in some retail stores. Both notifications name the same site among those: elegantfigure.com.
What the laboratory analysis found
The FDA’s notification on the first product says laboratory analysis confirmed Esbelta Intense Loss “contains sibutramine, desmethyl sibutramine, benzyl sibutramine and sildenafil not listed on the product label”. It describes sibutramine as “a controlled substance that was removed from the market due to safety concerns”, known to “significantly raise blood pressure and/or heart rate in some people”; the other two it calls structurally similar substances. Sildenafil it reports as a prescription active, with a nitrate interaction risk.
The second notification, published the same day, reports one substance in Esbelta Chupapanza Flat Belly: phenolphthalein. The FDA says it “is not an active ingredient in any approved drug in the U.S.” and that “studies suggest it may increase the risk of cancer”.
Five substances across two bottles, none of them on a panel. The notices report presence, not quantity — and quantity was never the question, because none of the five was declared.
Neither finding is new to the file
Both entries appear in the FDA’s public database of tainted products marketed as dietary supplements, dated 08/18/2026. The list held 2,197 entries on 29 August, the earliest from 2007. Of those, 366 name sibutramine or one of its structural analogues and 99 name phenolphthalein; 70 name both. Not an inventive adulterant, then, or a rare one — an old pair of names arriving again behind a new brand.
The one check available before buying
That database is public, but blunter than it looks. It carries warning letters and recalls as well as notifications like these two, and 592 of its 2,197 rows list no seller URL. So a check by product name costs a minute; a check by seller works only where the agency recorded one. The FDA also says it “is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients”. Absence is not a clearance; presence is an answer.
Be exact about what the agency did. No one examined either capsule before it shipped — supplements are not evaluated by the FDA ahead of sale, and nothing sold as one is intended to diagnose, treat, cure or prevent a disease. This was a laboratory test after the fact: a finding about two named products, not a verdict on a shelf. Anyone who has taken either should tell a doctor.